A large body of evidence places RIPK1/3-driven caspase-8 or MLKL signaling upstream of NLRP3 inflammasome activity in a range of disease settings (Gurung et al, 2014; Orning et al, 2018; Sarhan et al, 2018; Polykratis et al, 2019; Huang et al, 2021; Kim et al, 2022), yet their contribution to inflammasome activity in metabolic disease is less clear (Tao et al, 2021). Here, MLKL is linked to Other metabolic disease.